Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05281614 · ClinicalTrials.gov registry record · Early Phase 1
Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D
A Early Phase 1 study of Type 1 Diabetes, sponsored by Benaroya Research Institute.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 20
- Enrollment target
- 2
- Study locations
NCT05281614 is a Early Phase 1 study of Type 1 Diabetes that has completed, run by Benaroya Research Institute. The registered enrollment target is 20 participants, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT05281614, a Early Phase 1 study of Type 1 Diabetes, has completed, sponsored by Benaroya Research Institute.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 20 participants
- Enrollment target
- 2
- Study locations
Study Summary
The underlying hypothesis is that vedolizumab will modify immune cell trafficking in type 1 diabetes, and that this will be enhanced by pre-treatment with etanercept. This study will determine whether there is mechanistic evidence in support of this hypothesis and provide preliminary information about safety, efficacy, and tolerability of vedolizumab with and without pretreatment with etanercept in adults with type 1 diabetes (T1D)
Conditions Studied
Interventions
- DRUG Vedolizumab
- DRUG Etanercept
Study Locations (2)
California
- University of California San Diego - La Jolla
Washington
- Benaroya Research Institute - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-09-21 |
| Est. Completion | 2024-01-10 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05281614
The ClinicalTrials.gov registry entry for NCT05281614 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 824-participant average among 178 other Type 1 Diabetes trials with a reported enrollment target (98% lower). The listed sponsor is Benaroya Research Institute, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Type 1 Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Vedolizumab is the first listed.
NCT05281614 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Washington.
Frequently Asked Questions
What is clinical trial NCT05281614 about?
NCT05281614 is a clinical study titled "Immune Effects of Vedolizumab With or Without Anti-TNF Pre-treatment in T1D". The underlying hypothesis is that vedolizumab will modify immune cell trafficking in type 1 diabetes, and that this will be enhanced by pre-treatment with etanercept. This study will determine whether there is mechanistic evidence in support of this hypothesis and provide preliminary information abo...
What is the current status of trial NCT05281614?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 20 participants. The study started on 2022-09-21. Estimated completion is 2024-01-10.
What conditions does trial NCT05281614 study?
This clinical trial studies the following conditions: Type 1 Diabetes.
What interventions are being tested in trial NCT05281614?
The interventions under investigation include: Vedolizumab (DRUG), Etanercept (DRUG).
Who is sponsoring clinical trial NCT05281614?
This trial is sponsored by Benaroya Research Institute, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05281614 being conducted?
This trial has 2 study locations across California, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 1 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Type 1 Diabetes, Endothelin, and Skeletal Muscle Mitochondrial Dysfunction: The Role of Sirtuin-1
RECRUITING · Early Phase 1
-
GLP-1Ra Impact on Metabolic Outcomes in Stage 2 T1DM While Receiving Teplizumab
RECRUITING · Early Phase 1
-
Effect of C-peptide on Hypoglycemic Counterregulation
RECRUITING · Early Phase 1
-
Acceleration of Insulin Action by Hyaluronidase During Closed-Loop Therapy
COMPLETED · Early Phase 1
-
Early Markers of Disease and Response to Therapy
COMPLETED · Early Phase 1
-
MANATEE-T1D: Metformin ANd AutomaTEd Insulin Delivery System Effects on Renal Vascular Resistance, Insulin Sensitivity, and Cardiometabolic Function in Youth With Type 1 Diabetes
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.